Scribe Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCTX research report →
Range $37 – $60
Price Chart
About the company
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
- CEO
- Benjamin L. Oakes
- IPO
- 2026
- Employees
- 82
- HQ
- Alameda, CA, US
AI snapshot
Six angles, distilled from the data.
The stock is still in a post-IPO reset, trading well below its 200-day average of 22.88 and 50-day average of 21.13. The long-term range is wide, with the shares far under the 52-week high of 39.60 but above the 52-week low of 13.50, which keeps the setup in a recovery phase rather than a confirmed trend change.
Street coverage is constructive, with a Buy consensus and a 51.75 average target versus the latest close at 16.99. Recent initiations have all been positive, including Buy ratings at H.C. Wainwright and Guggenheim and Overweight at Wells Fargo, signaling early support despite the stock’s weak tape.
The earnings profile remains uneven: the last two quarters split between one beat and one miss, with the most recent quarter missing by 61.9%. Full-year 2026 EPS is still expected to be negative at -3.68, so shareholders should watch whether losses narrow and whether revenue tracks toward the 10.35 million estimate.
Insider activity leans bullish, led by large discretionary purchases from directors and a 10% owner, including 1,000,000-share buys by Carl L. Gordon and Orbimed Advisors LLC. The conversion-related filings add noise, but the cash purchases point to meaningful confidence from aligned holders.
Profitability remains deeply negative, with a gross margin of -202.8%, operating margin of -294.97%, and net margin of -294.35%. The balance sheet is a relative strength, with 57.96 million in cash, 41.43 million in debt, and 16.54 million in net cash, but operating cash flow was -45.21 million and free cash flow was -43.94 million in 2025.
SCTX sits in the high-risk, pre-profit biotech bucket, where valuation is driven more by pipeline progress than current earnings power. The stock trades at a negative P/E and a steep discount to the 51.75 consensus target, leaving room if execution improves, but the market is still pricing in heavy losses.
- Market Cap
- $195.32M
- P/E
- -1.52
- PEG
- -0.02
- P/S
- 33.75
- P/B
- 1.83
- EV/EBITDA
- -1.05
- Div Yield
- 0.00%
- Gross Margin
- 73.34%
- Op Margin
- -564.78%
- Net Margin
- -582.12%
- ROE
- -238.93%
- ROIC
- -21.59%
Latest fiscal year · YoY change
- Revenue
- $51.17M+0.0%
- Gross Profit
- $-9,621,000+0.0%
- Op Income
- $-26,070,000
- Net Income
- $-21,808,000+0.0%
- EPS
- $-1.24+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $39.60
- 52W Low
- $12.00
- 50D MA
- $19.92
- 200D MA
- $22.48
- Beta
- 0.00
- RSI (14)
- 31
- Avg Volume
- 401.37K
No earnings-call transcripts are available for SCTX yet.
- Free Float
- 10.5%
- Shares Outstanding
- 16.18M
- Float Shares
- 1.70M
of shares held by institutions
6 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 679.79K | ▲ 679.79K |
| Morgan Stanley | 8.54K | ▲ 8.54K |
| Kayne Anderson Rudnick Investment Management LLC | 4.20K | ▲ 4.20K |
| Steward Partners Investment Advisory, LLC | 1.00K | ▲ 1.00K |
Held by 105 ETFs
Biggest fund positions in SCTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 27, 26 | AH Bio Fund II, L.P. | buy | 333,333 |
| Jul 27, 26 | AH Bio Fund II, L.P. | other | 2,051,742 |
| Jul 27, 26 | AH Bio Fund II, L.P. | other | 697,650 |
| Jul 27, 26 | AH Bio Fund II, L.P. | other | 4,131,344 |
| Jul 27, 26 | AH Bio Fund II, L.P. | other | 12,150,003 |
| Jul 27, 26 | GORDON CARL L | buy | 1,000,000 |
| Jul 27, 26 | GORDON CARL L | other | 348,825 |
| Jul 27, 26 | GORDON CARL L | other | 2,065,672 |
| Jul 27, 26 | ORBIMED ADVISORS LLC | buy | 1,000,000 |
| Jul 27, 26 | ORBIMED ADVISORS LLC | other | 348,825 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SCTX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on SCTX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026
globenewswire.com · Nov 18
Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com · Nov 12
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
globenewswire.com · Nov 5
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
globenewswire.com · Nov 4
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
fool.com · Oct 20
Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst
seekingalpha.com · Oct 15
Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street Analysts
defenseworld.net · Sep 28
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com · Sep 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 16, 2026 · Live quote · Not investment advice